BRPI0507442A - métodos de diagnóstico e tratamento de pré-eclampsia ou eclampsia - Google Patents

métodos de diagnóstico e tratamento de pré-eclampsia ou eclampsia

Info

Publication number
BRPI0507442A
BRPI0507442A BRPI0507442-8A BRPI0507442A BRPI0507442A BR PI0507442 A BRPI0507442 A BR PI0507442A BR PI0507442 A BRPI0507442 A BR PI0507442A BR PI0507442 A BRPI0507442 A BR PI0507442A
Authority
BR
Brazil
Prior art keywords
methods
eclampsia
preeclampsia
treatment
diagnosis
Prior art date
Application number
BRPI0507442-8A
Other languages
English (en)
Inventor
S Ananth Karumanchi
Sharon Maynard
Vikas P Sukhatme
Original Assignee
Beth Israel Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/771,518 external-priority patent/US7335362B2/en
Application filed by Beth Israel Hospital filed Critical Beth Israel Hospital
Publication of BRPI0507442A publication Critical patent/BRPI0507442A/pt
Publication of BRPI0507442B1 publication Critical patent/BRPI0507442B1/pt
Publication of BRPI0507442B8 publication Critical patent/BRPI0507442B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1217—Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

MéTODOS DE DIAGNóSTICO E TRATAMENTO DE PRé-ECLAMPSIA OU ECLAMPSIA. A presente invenção refere-se a métodos para o tratamento de pré-eclampsia ou eclampsia, que são divulgados aqui usando compostos que aumentam os níveis de VEGF ou PIGF ou compostos que diminuem os níveis de sFIt-1. Também são descritos aqui, métodos para o monitoramento do tratamento de pré-eclampsia ou eclampsia através de detecção dos níveis de sFIt-1, VEGF ou PIGF. Também são descritos aqui métodos para diagnóstico de pré-eclampsia e eclampsia através de detecção dos níveis de sFIt-1, VEGF e PIGF em um indivíduo.
BRPI0507442A 2004-02-04 2005-02-04 método in vitro de diagnóstico de um indivíduo humano gestante como apresentando ou com uma propensão a desenvolver pré-eclâmpsia ou eclâmpsia BRPI0507442B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/771,518 2004-02-04
US10/771,518 US7335362B2 (en) 2002-07-19 2004-02-04 Methods of treating pre-eclampsia or eclampsia
US11/019,559 2004-12-21
US11/019,559 US7435419B2 (en) 2002-07-19 2004-12-21 Methods of diagnosing and treating pre-eclampsia or eclampsia
PCT/US2005/003884 WO2005077007A2 (en) 2004-02-04 2005-02-04 Methods of diagnosing and treating pre-eclampsia or eclampsia

Publications (3)

Publication Number Publication Date
BRPI0507442A true BRPI0507442A (pt) 2007-07-10
BRPI0507442B1 BRPI0507442B1 (pt) 2021-02-23
BRPI0507442B8 BRPI0507442B8 (pt) 2021-05-25

Family

ID=34859793

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507442A BRPI0507442B8 (pt) 2004-02-04 2005-02-04 método in vitro de diagnóstico de um indivíduo humano gestante como apresentando ou com uma propensão a desenvolver pré-eclâmpsia ou eclâmpsia

Country Status (10)

Country Link
US (2) US7435419B2 (pt)
EP (2) EP1718334A4 (pt)
JP (1) JP4711972B2 (pt)
KR (1) KR20070001991A (pt)
CN (1) CN1946423A (pt)
AU (1) AU2005213493A1 (pt)
BR (1) BRPI0507442B8 (pt)
CA (1) CA2554971A1 (pt)
ES (1) ES2404295T3 (pt)
WO (1) WO2005077007A2 (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7435419B2 (en) * 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
US7335362B2 (en) * 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
ES2534926T3 (es) * 2002-07-19 2015-04-30 Beth Israel Deaconess Medical Center Métodos para tratar la preeclampsia
AU2005244167A1 (en) * 2004-05-04 2005-11-24 Beth Israel Deaconess Medical Center Methods and compositions for treatment of preeclampsia
SG155257A1 (en) 2004-09-24 2009-09-30 Beth Israel Hospital Methods of diagnosing and treating complications of pregnancy
US7740849B2 (en) * 2004-09-24 2010-06-22 Beth Israel Deaconess Medical Center Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
DE602005023216D1 (de) 2004-12-15 2010-10-07 Beth Israel Hospital Nukleinsäuren und polypeptide zur diagnose und behandlung von schwangerschaftskomplikationen
AU2006226891A1 (en) * 2005-03-24 2006-09-28 Beth Israel Deaconess Medical Center Methods of diagnosing fetal trisomy 13 or a risk of fetal trisomy 13 during pregnancy
DE102005022047A1 (de) * 2005-05-09 2006-11-30 Dade Behring Marburg Gmbh Bindungspartner des Plazentalen Wachstumsfaktors insbesondere gegen den Plazentalen Wachstumsfaktor gerichtete Antikörper, ihre Herstellung und Verwendung
WO2007024752A2 (en) * 2005-08-26 2007-03-01 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of endothelial cell disorders and angiogenic disorders
WO2007030889A1 (en) * 2005-09-15 2007-03-22 Victor Voroteliak Method of diagnosing pre-eclampsia
US20070111326A1 (en) * 2005-11-14 2007-05-17 Abbott Laboratories Diagnostic method for proteinaceous binding pairs, cardiovascular conditions and preeclampsia
GB0600916D0 (en) * 2006-01-17 2006-02-22 Perkinelmer Instr Las Inc detecting and predicting pre-eclampsia
US20090286271A1 (en) * 2006-05-31 2009-11-19 Karumanchi Ananth S Methods of Diagnosing and Treating Complications of Pregnancy
US20080071151A1 (en) * 2006-06-30 2008-03-20 Sogin David C Method and Apparatus for Diagnosing Pre-eclampsia
US20090104649A1 (en) 2007-06-11 2009-04-23 Garovic Vesna D Markers for preeclampsia
JP5010034B2 (ja) * 2007-12-28 2012-08-29 エフ．ホフマン−ラ ロシュ アーゲー 生理学的状態の評価
WO2009089286A1 (en) * 2008-01-07 2009-07-16 Ortho-Clinical Diagnostics, Inc. Determination of sflt-1:angiogenic factor complex
US8148157B2 (en) * 2008-01-07 2012-04-03 Ortho-Clinical Diagnostics, Inc. Reference, calibrator, or control composition of PIGF-1 and sFlt-1
JP2009162616A (ja) * 2008-01-07 2009-07-23 Univ Of Tokyo オートタキシン測定による妊娠および妊娠高血圧症候群の検査方法および検査薬
EP2120051B1 (en) * 2008-05-13 2011-08-31 Roche Diagnostics GmbH Means and methods for predicting renal failure in diabetes patients based on placental growth factor and soluble FLT1
JP2011525241A (ja) * 2008-06-18 2011-09-15 アボット・ラボラトリーズ ＰｌＧＦ−１コンパニオン診断方法および製品
CA2741117A1 (en) * 2008-10-30 2010-05-06 Centre De Recherche Public De La Sante Biomarkers for heart failure
CN110208540B (zh) * 2008-10-31 2024-02-09 耶鲁大学 子痫前期检测和治疗的方法和组合物
US20130034861A1 (en) 2009-12-21 2013-02-07 Mayo Foundation For Medical Education And Research Early marker of proteinuria in patients treated with an anti-vegf treatment
AU2011252954B2 (en) 2010-05-14 2015-04-16 Beth Israel Deaconess Medical Center Extracorporeal devices and methods of treating complications of pregnancy
JP5963005B2 (ja) * 2010-07-19 2016-08-03 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 膵臓癌の治療のためのベバシズマブ組合せ療法のための血漿バイオマーカー
AU2011281706A1 (en) * 2010-07-19 2013-01-10 F. Hoffmann-La Roche Ag Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
GB201013151D0 (en) * 2010-08-04 2010-09-22 Isis Innovation Diagnostic method
KR101230740B1 (ko) * 2010-09-08 2013-02-07 인제대학교 산학협력단 자간전증의 조기 진단 및 예후 평가 방법
CA2826563C (en) 2011-02-07 2020-10-20 Paul Kussie Methods and systems for treating eclampsia and pre-eclampsia
ES2650263T3 (es) 2011-11-09 2018-01-17 F. Hoffmann-La Roche Ag Dinámica de la razón de SFLT-1 o endoglina/PLGF como indicador para preeclampsia inminente y/o síndrome de HELLP
KR20140114415A (ko) 2012-01-13 2014-09-26 제넨테크, 인크. Vegf 길항제로의 치료를 위한 환자를 확인하기 위한 생물학적 마커
RU2483311C1 (ru) * 2012-06-15 2013-05-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО РНИМУ им. Н.И. Пирогова Минздравсоцразви Способ диагностики преэклампсии у беременных с хронической артериальной гипертензией
WO2014001244A1 (en) 2012-06-27 2014-01-03 Roche Diagnostics Gmbh MEANS AND METHODS APPLYING sFlt-1/PlGF OR ENDOGLIN/PlGF RATIO TO RULE-OUT ONSET OF PREECLAMPSIA WITHIN A CERTAIN TIME PERIOD
KR101297886B1 (ko) * 2012-10-02 2013-08-19 인제대학교 산학협력단 자간전증의 조기 진단 및 예후 평가 방법
EP2965088B1 (en) 2013-03-04 2018-12-05 IQ Products B.V. Prognostic marker to determine the risk for early-onset preeclampsia
EP3097422B1 (en) * 2014-01-24 2018-07-11 Roche Diagnostics GmbH Prediction of postpartum hellp syndrome, postpartum eclampsia or postpartum preeclampsia
US10357469B2 (en) * 2015-02-18 2019-07-23 Aston University Diagnostic assay and treatment for preeclampsia
CN107690335A (zh) * 2015-04-07 2018-02-13 夏尔人类遗传性治疗公司 治疗支气管肺发育不良的抗flt‑1抗体
CN107683143A (zh) * 2015-04-07 2018-02-09 夏尔人类遗传性治疗公司 治疗支气管肺发育不良的抗flt‑1抗体
US10392665B2 (en) 2015-06-19 2019-08-27 Sera Prognostics, Inc. Biomarker pairs for predicting preterm birth
WO2017149027A1 (en) * 2016-03-01 2017-09-08 Koninklijke Philips N.V. Automated ultrasonic measurement of nuchal fold translucency
CA3022416A1 (en) * 2016-04-27 2017-11-02 Zietchick Research Institute, Llc Method for monitoring fetus/preterm infant development, and for promoting the normal development of preterm infants
EP4530633A3 (en) 2017-08-18 2026-03-25 Sera Prognostics, Inc. Pregnancy clock proteins for predicting due date and time to birth
US20200264188A1 (en) 2017-09-13 2020-08-20 Progenity, Inc. Preeclampsia biomarkers and related systems and methods
GB201806042D0 (en) * 2018-04-12 2018-05-30 Univ Oxford Innovation Ltd Biomarkers and uses thereof
CA3099275A1 (en) * 2018-05-09 2019-11-14 Dermtech, Inc. Novel gene classifiers and uses thereof in autoimmune diseases
WO2020102556A1 (en) * 2018-11-15 2020-05-22 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods of prognosis and classification for preeclampsia
GB2612911B (en) 2019-02-14 2023-11-22 Mirvie Inc Methods and systems for determining a pregnancy-related state of a subject
WO2021113710A1 (en) * 2019-12-04 2021-06-10 Progenity, Inc. Assessment of preeclampsia using assays for free and dissociated placental growth factor
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECLAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR TESTS
RU2717942C1 (ru) * 2019-12-20 2020-03-27 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации Способ диагностики преэклампсии по аминокислотному профилю плазмы крови
US20230132131A1 (en) * 2020-02-28 2023-04-27 Metabolomic Diagnostics Limited Prediction of risk of pre-eclampsia

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
WO1989009622A1 (en) 1988-04-15 1989-10-19 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
ES2070172T3 (es) 1988-04-16 1995-06-01 Celltech Ltd Procedimiento para producir proteinas mediante adn recombinante.
US5240848A (en) 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
US5238819A (en) 1988-12-14 1993-08-24 The Regents Of The University Of California Diagnostic assay for the detection of preeclampsia
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5219739A (en) 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
US5194596A (en) 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
US5712395A (en) 1992-11-13 1998-01-27 Yissum Research Development Corp. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5763441A (en) 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5895783A (en) * 1993-07-16 1999-04-20 Schering Aktiengesellschaft Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor
US6410322B1 (en) 1993-07-27 2002-06-25 Hybridon Inc Antisense oligonucleotide inhibition of vascular endothelial growth factor expression
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US5861499A (en) 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
WO1995022618A1 (en) 1994-02-22 1995-08-24 Dana-Farber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
US5543138A (en) 1994-03-10 1996-08-06 Genetics Institute, Inc. Methods of diagnosing and treating preeclampsia
US6613757B1 (en) * 1994-09-22 2003-09-02 Board Of Regents, The University Of Texas System Combination of prostacyclin with an estrogen or progestin for the prevention and treatment of atherosclerotic vascular disease including preeclampsia and for the treatment of hypertension, and for hormone replacement therapy
GB9512994D0 (en) 1995-06-26 1995-08-30 Brf International Method for quantitative measurement of an enzyme linked immunosorbent assay
US5830879A (en) 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6399585B1 (en) 1996-05-15 2002-06-04 Janet E. Larson In Utero treatment of CFTR-related deficiencies
CA2275708A1 (en) 1996-12-23 1998-07-02 Cambridge University Technical Services Limited Diagnosis and treatment of pathological pregnancies
US20010056068A1 (en) * 1998-03-04 2001-12-27 Kristof Chwalisz Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
US20030114407A1 (en) 2001-12-06 2003-06-19 Monia Brett P. Antisense modulation of G protein-coupled receptor ETBR-LP-2 expression
EP1417971A3 (en) 1998-09-09 2004-06-30 Scios Inc. Use of an angiogenic factor for the treatment of microvascular angiopathies
US6677300B1 (en) 1998-09-09 2004-01-13 Scios, Inc. Treatment of microvascular angiopathies
US7030083B2 (en) 1998-09-09 2006-04-18 University Of Washington Treatment of eclampsia and preeclampsia
US6245577B1 (en) 1998-09-11 2001-06-12 Midland Bioproducts Corporation IgG antibody testing method
AU759804B2 (en) 1998-09-28 2003-05-01 Skeleton Technologies Ag Method of manufacturing a diamond composite and a composite produced by same
EP1016726A1 (en) 1998-12-30 2000-07-05 Introgene B.V. Gene therapy to promote angiogenesis
PT1309726E (pt) 2000-03-30 2010-03-08 Whitehead Biomedical Inst Mediadores de interferência por rna específicos de sequência de rna
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
US6667300B2 (en) * 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
GB0026823D0 (en) 2000-11-02 2000-12-20 King S College London Diagnosis of pre-eclampsia
WO2002070535A1 (en) 2001-03-01 2002-09-12 Isis Pharmaceuticals, Inc. Antisense modulation of recql5 expression
ES2534926T3 (es) 2002-07-19 2015-04-30 Beth Israel Deaconess Medical Center Métodos para tratar la preeclampsia
US7435419B2 (en) * 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
US7335362B2 (en) 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
WO2005017192A2 (en) 2003-08-14 2005-02-24 The General Hospital Corporation Screening for gestational disorders
ES2556164T3 (es) * 2003-09-23 2016-01-13 The General Hospital Corporation Cribado de la preeclampsia
US7740849B2 (en) 2004-09-24 2010-06-22 Beth Israel Deaconess Medical Center Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
EP1839056B1 (en) 2004-12-21 2011-08-03 Yale University Diagnosis of preeclampsia
US8787344B2 (en) 2006-08-30 2014-07-22 Qualcomm Incorporated Method and apparatus for ACKCH with repetition in orthogonal systems
US8349325B2 (en) 2008-12-23 2013-01-08 Abbott Laboratories Soluble FMS-like tyrosine kinase-1 (sFLT-1) antibody and related composition, kit, methods of using, and materials and method for making

Also Published As

Publication number Publication date
US9518992B2 (en) 2016-12-13
JP4711972B2 (ja) 2011-06-29
ES2404295T3 (es) 2013-05-27
BRPI0507442B1 (pt) 2021-02-23
JP2007522457A (ja) 2007-08-09
US7435419B2 (en) 2008-10-14
HK1142535A1 (en) 2010-12-10
CA2554971A1 (en) 2005-08-25
KR20070001991A (ko) 2007-01-04
AU2005213493A1 (en) 2005-08-25
WO2005077007A2 (en) 2005-08-25
WO2005077007A3 (en) 2006-03-16
US20050170444A1 (en) 2005-08-04
EP1718334A2 (en) 2006-11-08
EP2172220A1 (en) 2010-04-07
EP2172220B1 (en) 2013-01-23
US20090117588A1 (en) 2009-05-07
CN1946423A (zh) 2007-04-11
BRPI0507442B8 (pt) 2021-05-25
EP1718334A4 (en) 2008-04-23

Similar Documents

Publication Publication Date Title
BRPI0507442A (pt) métodos de diagnóstico e tratamento de pré-eclampsia ou eclampsia
WO2013022953A3 (en) Biomarker for alzheimer's disease and/or mild cognitively impairment, and use thereof
EA200971079A1 (ru) ГЕНЕТИЧЕСКИЕ ВАРИАНТЫ В Chr5p12 И 10q26 В КАЧЕСТВЕ МАРКЕРОВ ДЛЯ ПРИМЕНЕНИЯ ПРИ ОЦЕНКЕ РИСКА, ДИАГНОСТИРОВАНИИ, ПРОГНОЗИРОВАНИИ И ЛЕЧЕНИИ РАКА ГРУДИ
EA201391587A1 (ru) Комбинированная терапия на основе hsp90
WO2012018535A3 (en) Wellness panel
WO2007126758A3 (en) Method and system for determining whether a drug will be effective on a patient with a disease
BR112013000745A2 (pt) "método para diagnosticar ou detectar câncer colorretal em um individuo, método de tratamento e método para monitorar a eficacia de tratamento de câncer colorretal em um indivíduo"
WO2005028675A3 (en) Methods for detecting, diagnosing and treating hepatocellular carcinomas (hcc)
WO2012142301A3 (en) Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
WO2010036960A8 (en) Methods for treating, diagnosing, and monitoring lupus
BR112019004075A2 (pt) métodos para diagnosticar um indivíduo com suspeita de endometriose, para detectar mirna, para diagnosticar um indivíduo que apresenta sintomas de endometriose ou com suspeita de endometriose, para tratar um indivíduo com endometriose, para diagnosticar e tratar um indivíduo com suspeita de endometriose, para diagnosticar endometriose em um indivíduo, para diagnosticar ou prover um prognóstico para endometriose em um indivíduo e para monitorar uma resposta a um tratamento de endometriose em um indivíduo, e, kit.
WO2009038689A3 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
BR112016018205A2 (pt) métodos de tratamento de mal de alzheimer
WO2010082944A3 (en) Systems and methods for imaging changes in tissue
WO2013071119A3 (en) Methods for treating, diagnosing and monitoring alzheimer's disease
WO2008030273A3 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
WO2008141148A3 (en) Characterization of the cbir1 antigenic response for diagnosis and treatment of crohn's disease
WO2007136617A3 (en) Endothelial-monocyte activating polypeptide ii, a biomarker for use in diagnosis of brain injury
EA201590024A1 (ru) Способы определения заболеваний или состояний с применением циркулирующих болезненных клеток
WO2011052906A3 (en) Use of eif3m for the diagnosis and treatment of cancer
MX367192B (es) Sistemas de cuantificacion de patogenesis y metodos de tratamiento para el enverdecimiento de los citricos.
WO2015070191A3 (en) Systems and methods for detection of genomic variants
WO2008089135A3 (en) Identification of biomarkers predictive of dasatinib effects in cancer cells
BR112019006404A2 (pt) métodos para diagnóstico e tratamento de câncer de próstata metastático resistente à castração sensível ou resistente a acetato de abiraterona-glicocorticoide
WO2006059252A3 (en) Methods and fluorinated compositions for treating amyloid-related diseases

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/02/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/02/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2865 DE 02-12-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.